Several anti-DLL4 monoclonal antibodies have successfully demonstrated broad preclinical antitumor activity, with multiple anti-DLL4 molecules currently investigated as potential cancer therapeutics 33, 42, 66-68. The gene discussed is DLL4; the disease is cancer.